By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
CinCor Pharma is developing a “pipeline in a product” for the long-quiet area of hypertension, specifically the kind that existing treatments fail to control. The first three programs are in its broader target area of cardio-renal disease, testing a single drug. Coded CIN-107, the once-daily oral drug is a “highly specific” aldosterone synthase inhibitor (ASI) now in three Phase 2 programs, one focused on treatment-resistant hypertension (rHTN), another on uncontrolled hypertension (uHTN), and the third on primary aldosteronism (PA).